echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Mercedon 15-price pneumonia vaccine reached a critical clinical end and submitted a regulatory application by the end of the year.

    The Mercedon 15-price pneumonia vaccine reached a critical clinical end and submitted a regulatory application by the end of the year.

    • Last Update: 2020-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pneumococcal disease is an infection caused by Streptococcus pneumoniae.
    Highly invasive strains or serotypes may put more people at risk of non-invasive pneumococcal diseases (e.g. pneumococcal pneumonia, sinusitis and otitis mesothitis) and invasive pneumococcal diseases (e.g., pneumococcalemia, bacteremia pneumonia and pneumococcal meningitis).
    while healthy adults and children may develop pneumococcal disease, susceptible groups include children under 2 years of age, people over 65 years of age, and people with immunosuppression or certain chronic diseases.
    V114 is a 15-price pneumococcal combination vaccine developed in Mercedon to prevent pneumococcal disease in adults and children.
    it consists of 15 serotonin polysaccharides, including serotonin 22F and 33F, that bind to CRM197 carrier proteins.
    these serotypes are usually associated with global invasive pneumococcal disease and are not included in the pneumococcal binding vaccine currently approved for adult use.
    In addition to reaching the primary endpoint, the PNEU-AGE trial also reached a critical secondary immunogenic endpoint, demonstrating the effectiveness of V114 in serum type 3 (the main cause of global invasive pneumococcal disease) compared to PCV13.
    in another Phase 3 clinical study, PNEU-TRUE, three different batches of V114 in healthy adults over the age of 50 had the same immune response in all 15 serotypes.
    two studies, V114 showed good tolerance and safety characteristics.
    "There is a global increase in serotype-related diseases that are not covered by the pneumococcal binding vaccine."
    In addition, we continue to see pneumococcal diseases caused by serotonin contained in existing pneumococcal vaccines," said Dr. Roy Baynes, Chief Medical Officer, Mercaton Laboratory and Head of Global Clinical Development.
    these Phase 3 clinical trial data show that all 15 serotypes included in the V114 pair of vaccines trigger a strong immune response, further demonstrating the potential of the vaccine in the study to help adults fight pneumococcal disease.
    " References: s1. Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial. Retrieved September 9, 2020, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.